Table 1.

Baseline patient characteristics (N = 35)

Characteristic	n	%
Age (years)
Median	61
Range	42–81
Gender
Female	4	11
Male	31	89
ECOG performance status
0	6	17
1	23	66
2	6	17
Location of primary tumor
Esophageal	12	34
GE junction	8	23
Gastric	15	43
Location of metastasesa
Lymph nodes	24	69
Liver	20	57
Bone	9	26
Lung	7	20
Peritoneum	8	23
No. of prior chemotherapy regimens
1	9	26
2	26	74
Prior treatment
Cisplatin/irinotecan	14	40
5-fluorouracil/leuocovorin/oxaliplatin	6	17
Docetaxel/cisplatin/irinotecan/bevacizumab	6	17
Docetaxel/cisplatin/irinotecan	4	11
Epirubicin/cisplatin/fluorouracil	4	11
Docetaxel/bevacizumab	4	11
Docetaxel	3	9
Otherb

^aDoes not sum to 100%, as patients may have metastases to more than one location.

^bOther prior chemotherapy regimens include the following: epirubicin–cisplatin–capecitabine (1), epirubicin–oxaliplatin–capecitabine (2), cisplatin–docetaxel (1), cisplatin–5-fluorouracil (1), capecitabine–oxaliplatin (2), cisplatin–irinotecan–capecitabine (2), irinotecan (1), 5-fluorouracil–leucovorin–irinotecan (1), capecitabine (1), capecitabine–docetaxel (1), carboplatin–paclitaxel (1), XL880 (1), cyclophosphamide–methotrexate–celecoxib (1).

ECOG, Eastern Cooperative Oncology Group; GE, gastroesophageal.